| SEC Form | 1 4 |
|----------|-----|
|----------|-----|

# FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

| OMB Number:              | 3235-0287 |  |  |  |  |  |  |
|--------------------------|-----------|--|--|--|--|--|--|
| Estimated average burden |           |  |  |  |  |  |  |
| hours per response:      | 0.5       |  |  |  |  |  |  |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1. Name and Address of Reporting Person <sup>*</sup><br>Moreland Mary K | 2. Issuer Name and Ticker or Trading Symbol <u>ABBOTT LABORATORIES</u> [ ABT ] | 5. Relationship of Reporting Person(s) to Issuer<br>(Check all applicable)<br>Director 10% Owner<br>Officer (give title Other (specify  |
|---|--|---|
| (Last) (First) (Middle)<br>100 ABBOTT PARK ROAD                         | 3. Date of Earliest Transaction (Month/Day/Year)<br>02/19/2021                 | X below) below)<br>EXECUTIVE VICE PRESIDENT   |
| (Street)<br>ABBOTT PARK IL 60064<br>(City) (State) (Zip)                | 4. If Amendment, Date of Original Filed (Month/Day/Year)                       | <ul> <li>6. Individual or Joint/Group Filing (Check Applicable<br/>Line)</li> <li>X Form filed by One Reporting Person</li> <li>Form filed by More than One Reporting<br/>Person</li> </ul> |

### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction<br>Date<br>(Month/Day/Year) | 2A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) | 3.<br>Transa<br>Code (<br>8) |   | 4. Securities Acquired (A) or<br>Disposed Of (D) (Instr. 3, 4 and 5) |               |             | 5. Amount of<br>Securities<br>Beneficially<br>Owned Following<br>Reported | 6. Ownership<br>Form: Direct<br>(D) or Indirect<br>(I) (Instr. 4) | 7. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |
|---------------------------------|--|---|------------------------------|---|--|---------------|-------------|---|---|---|
|                                 |  |   | Code                         | v | Amount   | (A) or<br>(D) | Price       | Transaction(s)<br>(Instr. 3 and 4)  |   | (iiisu. 4)  |
| Common shares without par value | 02/19/2021                                 |   | A                            |   | 13,513(1)  | A             | \$ <u>0</u> | 76,886  | D   |   |
| Common shares without par value | 02/22/2021                                 |   | F                            |   | 780  | D             | \$123.04    | 76,106  | D   |   |
| Common shares without par value | 02/22/2021                                 |   | S                            |   | 400  | D             | \$121.835   | 75,706  | D   |   |
| Common shares without par value |  |   |                              |   |  |               |             | 10,826 <sup>(2)</sup>   | Ι   | Profit<br>Sharing<br>Trust  |

#### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

|   | (e.g., puts, cans, warrants, options, convertible securities)         |  |   |                              |   |        |     |  |                    |   |  |   |  |  |  |
|---|---|--|---|------------------------------|---|--------|-----|--|--------------------|---|--|---|--|--|--|
| 1. Title of<br>Derivative<br>Security<br>(Instr. 3) | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction<br>Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) | 4.<br>Transa<br>Code (<br>8) |   | of     |     | 6. Date Exercisable and<br>Expiration Date<br>(Month/Day/Year) |                    | 7. Title and Amount<br>of Securities<br>Underlying<br>Derivative Security<br>(Instr. 3 and 4) |  | 8. Price of<br>Derivative<br>Security<br>(Instr. 5) | 9. Number of<br>derivative<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported<br>Transaction(s)<br>(Instr. 4) | 10.<br>Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I) (Instr. 4) | 11. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |
|   |   |  |   | Code                         | v | (A)    | (D) | Date<br>Exercisable  | Expiration<br>Date | Title   | Amount<br>or<br>Number<br>of<br>Shares |   |  |  |  |
| Option<br>(right to<br>buy) <sup>(3)</sup>          | \$124.04  | 02/19/2021                                 |   | Α                            |   | 69,266 |     | 02/19/2022   | 02/18/2031         | Common<br>Shares  | 69,266                                 | \$0   | 69,266   | D  |  |

### Explanation of Responses:

1. These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.

2. Balance in the Abbott Laboratories Stock Retirement Trust as of February 19, 2021.

3. Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 23,088 on February 19, 2022, 23,089 on February 19, 2023, and 23,089 on February 19, 2024.

## <u>/s/ Mary K. Moreland by</u> Jessica H. Paik, Attorney-in-

Fact

\*\* Signature of Reporting Person Date

02/23/2021

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.